Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EBITDA (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of EBITDA data on record, last reported at $780.0 million in Q4 2025.

  • For Q4 2025, EBITDA rose 1595.65% year-over-year to $780.0 million; the TTM value through Dec 2025 reached $892.0 million, up 1974.42%, while the annual FY2025 figure was $960.0 million, 2426.32% up from the prior year.
  • EBITDA reached $780.0 million in Q4 2025 per INDV's latest filing, up from $43.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $780.0 million in Q4 2025 and bottomed at -$97.0 million in Q2 2024.